Statement: Farletuzumab and the FAR 122 Study

Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based on the results of an interim analysis conducted by an Independent Data Monitoring Committee (IDMC) that determined the study was unlikely to meet its statistically defined endpoints of progression-free survival and overall survival. Morphotek has notified investigators of this discontinuation.

Neither Morphotek nor the IDMC has identified safety issues that impact this decision.

Platinum-resistant ovarian cancer refers to a late stage of ovarian cancer which no longer responds to platinum containing chemotherapy and has an extremely poor prognosis.

The Phase III study (FAR 131) with farletuzumab in patients with platinum-sensitive ovarian cancer is still ongoing and currently recruiting. For more information, please visit

Type Press Release

Date Released December 02, 2011

Apr 19, 2021

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...

Apr 16, 2021

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...

Apr 11, 2021

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its animation “Leave No One Behind-Disease of Neglected People” which features activities for the...

Alerts - Release page
* Required Fields